Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Propofol Anesthesia
Launched by TAMAS VEGH, MD · Jun 27, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how safe and effective a medicine called Sugammadex is for reversing muscle relaxation caused by certain drugs used during general anesthesia. When patients have surgery, muscle relaxants like Pipecuronium or Rocuronium are often given to help with breathing and surgery conditions, but these muscles need to work again properly after the operation. This study will carefully monitor how quickly and safely Sugammadex can reverse the muscle relaxation, making sure patients recover muscle strength without any leftover weakness or allergic reactions.
The study will include about 80 adult patients aged 18 to 65 who are having planned general or brain surgery lasting at least 40 minutes and requiring a breathing tube. Participants should be generally healthy with a normal body weight and no serious muscle, liver, or kidney problems. During the surgery, patients will receive standard monitoring to track their vital signs and muscle function, and after surgery, doctors will check to ensure the muscle relaxants have fully worn off. This study aims to provide clear information about the safety and recovery process when using these muscle relaxants and Sugammadex, helping improve care for patients undergoing anesthesia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 80 adult general surgery, neurosurgery patients were recruited in our study after giving an informed written consent to participate in the studies;
- • Age: between 18-65 years;
- • ASA score: 1-3;
- • BMI 18.5-25 (normal body weight);
- • Males and females were recruited in an equal ratio;
- • Minimal surgical time of at least ≥ 40 minutes;
- • Procedures requiring endotracheal intubation
- Exclusion Criteria:
- • Diseases affecting neuromuscular function (myopathies, severe liver and kidney failure);
- • Drugs affecting neuromuscular function (magnesium, aminoglycosides);
- • Difficult airway, or anticipated difficult intubation;
- • Pregnancy (a pregnancy test is performed in women of childbearing age to rule out pregnancy);
- • Breast-feeding;
- • Acute surgery;
- • COPD
- • Glaucoma
- • History of previous allergic/anaphylactic reactions
About Tamas Vegh, Md
Dr. Tamas Vegh, MD, is an esteemed clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic approaches, Dr. Vegh leads trials that explore novel treatments and interventions across various medical disciplines. His dedication to rigorous scientific methodology and ethical standards ensures that each study not only contributes to the body of medical knowledge but also prioritizes participant safety and well-being. Through collaboration with leading research institutions and healthcare professionals, Dr. Vegh aims to bridge the gap between research and clinical practice, ultimately enhancing the standard of care for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Debrecen, , Hungary
Patients applied
Trial Officials
László Asztalos, MD PhD
Principal Investigator
University of Debrecen, Faculty of Medicine, Department of Anaesthesiology and Intensive Care
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported